SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

Core Viewpoint - SeaStar Medical Holding Corporation has entered into a securities purchase agreement for the issuance and sale of 3,529,412 shares of common stock and accompanying warrants, aiming to raise approximately $6 million for general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement, with a combined offering price of $1.70 per share and accompanying warrants [1]. - The pre-funded warrants will have an exercise price of $0.001 per share and will be exercisable immediately upon issuance [1]. - The warrants will have an exercise price of $1.70 per share, exercisable upon shareholder approval, and will expire five years after the approval date [1][2]. Group 2: Financial Advisor and Closing Conditions - H.C. Wainwright & Co. is acting as the exclusive financial advisor for SeaStar Medical in connection with this offering [2]. - The closing of the offering is expected around February 3, 2025, subject to customary closing conditions [2]. Group 3: Regulatory Compliance - The shares and warrants are being offered under a shelf registration statement previously filed with the SEC, which became effective on December 22, 2023 [3]. - The securities offered in the registered direct offering will be available through a prospectus filed with the SEC [3]. Group 4: Company Overview - SeaStar Medical is a commercial-stage therapeutic medical technology company focused on developing extracorporeal therapies to mitigate excessive inflammation in critically ill patients [5]. - The company aims to provide innovative solutions targeting effector cells that drive systemic inflammation, which can cause direct tissue damage [5].